ABEO News & Analysis
3 articles
Market Mood
Abeona (ABEO) Reports $11.4M Q2 Revenue Growth of 31%
On August 13, Abeona Therapeutics (NASDAQ: ABEO) reported second-quarter revenue of $11.4 million, up 31% from $8.7 million in the prior quarter. The company has treated 12 patients with its gene therapy ZEVASKYN, expanding its treatment center network to seven sites, including Cincinnati Children's. Despite the revenue growth, net losses widened to $20.2 million, or $0.35 per share. The company's new technology payment from Medicare, effective October 1, 2026, highlights ongoing support for its innovative treatments, making it relevant for investors monitoring biotech advancements.
Read More: Abeona (ABEO) Reports $11.4M Q2 Revenue Growth of 31%
Form 144 ABEONA THERAPEUTICS INC. Filed on June 15
On June 15, ABEONA THERAPEUTICS INC. (ABEO) filed Form 144, which permits the sale of restricted securities. This filing indicates the company's intention to sell shares, which could impact share liquidity and investor sentiment. Such forms are typically filed by insiders or affiliates of the company, detailing their selling plans and intentions. This event can have market ramifications, particularly concerning trading volumes and stock price fluctuations.
Read More: Form 144 ABEONA THERAPEUTICS INC. Filed on June 15
Abeona Therapeutics (ABEO) Director Sells $103,695 in Stock
Christine Silverstein, a director at Abeona Therapeutics (ABEO), sold shares worth $103,695. This transaction adds to the recent trend of insider selling within the company. Such insider sales may influence investor perceptions and market reactions. Tracking these sales is essential for understanding management's confidence in the company's future performance.
Read More: Abeona Therapeutics (ABEO) Director Sells $103,695 in Stock